Brett Jepson, MS

Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA

Disclosure(s): AstraZeneca: Contractor via Cytel

Poster(s):

• 1953 - Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET